We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-1.06%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$716M
AUM Growth
-$19.1M
Cap. Flow
+$8.71M
Cap. Flow %
1.22%
Top 10 Hldgs %
27.06%
Holding
107
New
3
Increased
17
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$11.4M
2
VCYT icon
Veracyte
VCYT
+$10M
3
LOW icon
Lowe's Companies
LOW
+$3.19M
4
CPN
Calpine Corporation
CPN
+$2.73M
5
LYB icon
LyondellBasell Industries
LYB
+$2.16M

Top Sells

Rank Stock Value
1
ROC
ROCKWOOD HLDGS INC
ROC
+$12.9M
2
SDRL
Seadrill Limited Common Stock
SDRL
+$9.17M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.54M
4
UFS
DOMTAR CORPORATION (New)
UFS
+$2.29M
5
SZYM
SOLAZYME INC COM STK (DE)
SZYM
+$1.82M

Sector Composition

Rank Sector Weight
1 Healthcare 29.21%
2 Technology 14.59%
3 Consumer Discretionary 13.52%
4 Industrials 8.55%
5 Energy 5.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCI icon
26
Crown Castle
CCI
$33.4B
$10.5M 1.47%
130,700
– –
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$4.55B
$10.5M 1.46%
423,200
– –
STKL
28
DELISTED
SunOpta
STKL
$10.3M 1.43%
849,600
+15,000
+2% +$198K
IPHI
29
DELISTED
INPHI CORPORATION
IPHI
$9.84M 1.37%
684,200
+50,000
+8% +$728K
PCYC
30
DELISTED
PHARMACYCLICS INC
PCYC
$9.7M 1.35%
82,600
– –
TEX icon
31
Terex
TEX
$7.11B
$9.64M 1.35%
303,500
– –
PTLA
32
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$9.41M 1.31%
372,400
– –
CXP
33
DELISTED
COLUMBIA PROPERTY TRUST, INC.
CXP
$9.4M 1.31%
393,800
– –
ININ
34
DELISTED
Interactive Intelligence Group, inc.
ININ
$9.29M 1.3%
222,200
+38,000
+21% +$1.71M
ASML icon
35
ASML
ASML
$634B
$9.27M 1.29%
93,800
– –
VMW
36
DELISTED
VMware, Inc
VMW
$9.18M 1.28%
97,800
– –
FPRX
37
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$9.07M 1.27%
773,600
– –
VCYT icon
38
Veracyte
VCYT
$4.77B
$8.94M 1.25%
917,000
+762,300
+493% +$10M
NVAX icon
39
Novavax
NVAX
$1.22B
$7.96M 1.11%
95,435
– –
CMRE icon
40
Costamare
CMRE
$1.87B
$7.91M 1.1%
360,200
– –
NRG icon
41
NRG Energy
NRG
$28.3B
$7.72M 1.08%
253,400
– –
STML
42
DELISTED
Stemline Therapeutics, Inc.
STML
$7.22M 1.01%
579,800
+20,000
+4% +$246K
LGND icon
43
Ligand Pharmaceuticals
LGND
$5.94B
$7.03M 0.98%
239,969
– –
UFS
44
DELISTED
DOMTAR CORPORATION (New)
UFS
$6.98M 0.97%
198,600
-60,000
-23% -$2.29M
OII icon
45
Oceaneering
OII
$4.74B
$6.77M 0.95%
103,900
– –
PWR icon
46
Quanta Services
PWR
$98.7B
$6.63M 0.93%
182,800
– –
BWA icon
47
BorgWarner
BWA
$13.2B
$6.61M 0.92%
142,682
– –
AYR
48
DELISTED
Aircastle Ltd
AYR
$6.54M 0.91%
399,600
– –
TSLA icon
49
Tesla
TSLA
$1.22T
$6.38M 0.89%
394,500
– –
FC icon
50
Franklin Covey
FC
$243M
$6.18M 0.86%
315,600
– –
1
2
3 4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Eventide Asset Management held 107 positions worth $716M, down 2.6% from $735M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management's Q3 2014 filing shows 3 new, 17 increased, 4 reduced and 4 closed positions. Its largest new stake was Sage Therapeutics: 40,200 shares worth $1.27M. The largest sale was ROCKWOOD HLDGS INC, an estimated $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 27% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q3 2014 buy was Sage Therapeutics: 40,200 shares worth $1.27M.
  • Eventide Asset Management added most to bluebird bio in Q3 2014, an estimated $11.4M increase.
  • Eventide Asset Management's biggest Q3 2014 reduction was Agios Pharmaceuticals, cutting an estimated $2.54M.
  • Eventide Asset Management fully exited ROCKWOOD HLDGS INC in Q3 2014, selling an estimated $12.9M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $716M portfolio in Q3 2014.
  • Eventide Asset Management opened 3 new positions and closed 4 in Q3 2014.
  • Eventide Asset Management's portfolio value fell 2.6% quarter-over-quarter to $716M.

Based on Eventide Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.